

January 17, 2013
Announcement no. 01

Siemens Diagnostics' sales activities for NGAL suspended until further

BioPorto has received notification from Siemens Diagnostics of a communication to their international subsidiaries putting a halt to sales activities concerning The NGAL Test™. Siemens will refer interested customers to BioPorto. BioPorto is now looking further into the reasons for this and the prospects for activities being resumed.

On December 10, 2012, Siemens Diagnostics issued a marketing letter to their international subsidiaries on the sales cooperation with BioPorto, as described in company announcement no. 23 dated November 29, 2012.

Further information:

Thea Olesen, CEO

Christina Thomsen, Investor Relations

Tel. +45 45 29 00 00, e-mail investor@bioporto.com